The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I substance in the United States, meaning the only legal access pathways are through active...
This psychedelic therapy FAQ compiles the most common and most important questions from people seriously considering psilocybin or other psychedelic-assisted approaches. The answers here are grounded in current clinical research, verified legal data, and practical...
Psychedelic policy in the USA is moving faster in 2026 than at any point in recent history. A federal executive order, a wave of state-level bills, and advancing clinical trials have all converged in the first half of this year. This guide covers the key federal...
Couples psychedelic therapy is an emerging clinical area with early but substantive evidence behind it. Professionally supported shared experiences using MDMA or psilocybin can reduce relational rigidity, improve communication, and address post-trauma dynamics. They...
Talking to your doctor about psychedelic therapy is one of the most common points where people get stuck. This guide walks you through how to frame the conversation, what questions to bring, and what to understand about medications like SSRIs before you book that...
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single guided dose can produce meaningful, lasting reductions in PTSD symptoms. The evidence is promising, but also...
